Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Fos does not interact with Jun but homodimerizes post axotomy. by Gibarni Mahata (19486154)

Graphical abstract regarding program development. by Ana Beato (20489933)

“…<div><p>The stigma surrounding mental health remains a significant barrier to help-seeking and well-being in youth populations. …”

Phases of the intervention program. by Ana Beato (20489933)

“…<div><p>The stigma surrounding mental health remains a significant barrier to help-seeking and well-being in youth populations. …”

Influence of Postsynthetic Ligand Exchange in ZIF‑7 on Gate-Opening Pressure and CO₂/CH₄ Mixture Separation by Lukas W. Bingel (9371686)

“…The field of flexible metal–organic frameworks (MOFs) has garnered significant attention from researchers due to their potential for gas storage and capture applications. …”

Consort diagram. by Ana Beato (20489933)

“…<div><p>The stigma surrounding mental health remains a significant barrier to help-seeking and well-being in youth populations. …”

Influence of Postsynthetic Ligand Exchange in ZIF‑7 on Gate-Opening Pressure and CO₂/CH₄ Mixture Separation by Lukas W. Bingel (9371686)

“…The field of flexible metal–organic frameworks (MOFs) has garnered significant attention from researchers due to their potential for gas storage and capture applications. …”

Characteristics of the sample. by Ana Beato (20489933)

“…<div><p>The stigma surrounding mental health remains a significant barrier to help-seeking and well-being in youth populations. …”

Baseline analysis, nominal factors. by Hiroaki Yoshikawa (4615801)

“…Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. In contrast, the rates of thymectomy and both maximum and current oral steroid dosages decreased during this period.…”

Minimal dataset for the study. by Hiroaki Yoshikawa (4615801)

“…Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. In contrast, the rates of thymectomy and both maximum and current oral steroid dosages decreased during this period.…”

Baseline analysis, continuous factors. by Hiroaki Yoshikawa (4615801)

“…Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. In contrast, the rates of thymectomy and both maximum and current oral steroid dosages decreased during this period.…”

Multivariable analysis between 2006 and 2018. by Hiroaki Yoshikawa (4615801)

“…Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. In contrast, the rates of thymectomy and both maximum and current oral steroid dosages decreased during this period.…”

Navigation error analysis. by Haichao Li (225035)

“…Results show that SIDFM reduces navigation errors by 12.09% at low acceleration and 11.43% at high acceleration while also significantly decreasing positioning errors. These improvements enhance the stability, precision, and safety of AGVs in dynamic manufacturing environments. …”

Summary of related works. by Haichao Li (225035)

“…Results show that SIDFM reduces navigation errors by 12.09% at low acceleration and 11.43% at high acceleration while also significantly decreasing positioning errors. These improvements enhance the stability, precision, and safety of AGVs in dynamic manufacturing environments. …”

Research methodology flow diagram. by Haichao Li (225035)

“…Results show that SIDFM reduces navigation errors by 12.09% at low acceleration and 11.43% at high acceleration while also significantly decreasing positioning errors. These improvements enhance the stability, precision, and safety of AGVs in dynamic manufacturing environments. …”

Positioning error analysis. by Haichao Li (225035)

“…Results show that SIDFM reduces navigation errors by 12.09% at low acceleration and 11.43% at high acceleration while also significantly decreasing positioning errors. These improvements enhance the stability, precision, and safety of AGVs in dynamic manufacturing environments. …”